Lilly's lung cancer drug hits main goal in late-stage trial

08/14/2013 | Reuters · Pharmaceutical Business Review Online

Eli Lilly and Co.'s experimental drug necitumumab, or IMC-11F8, in combination with gemcitabine and cisplatin, met the primary goal of a Phase III trial by improving overall survival in patients with stage 4 squamous nonsmall-cell lung cancer compared with chemotherapy alone. The firm plans to submit the drug for FDA approval next year as a first-line therapy for squamous lung cancer. If approved, necitumumab would be the first biologic therapy for the condition.

View Full Article in:

Reuters · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI